树突细胞免疫疗法

 

 

 

 

1973年免疫学家和细胞生物学家拉尔夫·斯坦曼发现一种与免疫有关的新细胞,并将其命名为树突细胞。

2011年科学家拉尔夫·斯坦曼因在“树突状DC细胞及其在适应性免疫系统方面作用的发现”取得的成就,授予2011年诺贝尔生理学或医学奖,并获得2011年诺贝尔生理学或医学奖的一半奖金。

In 1973, Ralph Marvin Steinman, a Canadian immunologist and cell biologist, found a new immune cell and named it “Dendritic Cell”.

In 2011, the Committee for Physiology or Medicine announced that Ralph Steinman had received one-half of the Nobel Prize in Physiology or Medicine, for "his discovery of the dendritic cell and its role in adaptive immunity".

 

 

研究发现:30%的人群体内正在萌芽癌症,可惜他们全然不知。癌细胞来源于人体正常细胞,人体的防御系统常常无法及时发现并清除它们。通过防癌疫苗对癌细胞表面抗原的标记,就能使癌细胞“暴露身份”,成为众矢之的,树突细胞就是拥有这种功能的细胞。远离癌症,早防患胜于晚治疗!

 

According to the survey, some cancer is germinating in the body of 30% of the population. However, it’s a pity that they don’t know it at all. Cancer cell derives from human’s normal cell and the body’s defense system sometimes fails to find and eliminate them. Cancer vaccine can recognize cancer cell and mark it on cancer cell surface antigen so that the defense system can quickly find and destroy them. Dendritic cell is the cell with this kind of function. If you want to keep away from cancer, you’d better take early measures to prevent it than receive treatment after suffering from it.

 


树突细胞免疫疗法是一种运用病人自身免疫系统来抗击癌症的疗法。我们可以将这种安全温和的免疫疗法应用于健康人群,加强自身免疫系统,避免重大疾病的萌芽。

 

Dendritic Cell Therapy is a kind of immunotherapy that uses the patient’s own immune system to fight cancer. We may utilize the safe and gentle Dendritic Cell Immunotherapy in symptomless members of population to strengthen their immune system and avoid the development of serious diseases.

 

 

树突细胞免疫疗法的原理

The Principle of DC Immunotherapy

 

 

人体的血液中的白血球免疫系统中的淋巴细胞分为T细胞和NK细胞,它们是负责处理变异细胞的。T细胞又分为三种种类,分别为T-help哨兵功能细胞,负责发现变异细胞并记忆变异细胞;T-supervisor指令细胞,接受哨兵细胞发现变异细胞的信息,发送给执行细胞消除变异细胞;T-killer执行细胞,用来消除变异细胞。树突细胞免疫疗法可以激发更多的T细胞和NK细胞的生成,可以调节三种T细胞的均衡性,可以使相同数量的T细胞在体内的工作效率提高,还可以帮助记忆性的哨兵细胞更好地识别和记忆变异细胞,当同样的变异细胞产生时可以更有效更快速地识别并传达指令给指令细胞。癌细胞一定是变异细胞,因此及时消除或降低变异细胞的数量可以降低并避免患癌症的概率。

Our blood contains white blood cell immunity system. The lymphocytes of white blood cell immunity system are divided into T cells and NK cells that are responsible for handling mutant cells. There are three kinds of T cells: T-help, T-supervisor and T-killer. T-help is responsible for finding the mutant cells and remembering them. T-supervisor is in charge of receiving the message from T-help cells and sending the message to T-killer cells. T-killer cells is to kill the mutant cells. DC therapy can inspire the generation of T cells and NK cells, adjust the balance of the three kinds of T cells to improve their efficiency, help T-help-memory better remember and recognize the mutant cells when they meet them next time. Cancer cell derives from mutant cells so timely elimination and reduction of mutant cells will definitely lower or avoid the risk of suffering from cancer.

 

树突细胞免疫疗法适应症:

1. 作为传统癌症治疗的一种补充方法。

2. 治疗溃疡性结肠炎。

3. 治疗其他自身免疫疾病。

4. 作为病人预防癌症或者其他疾病的一种预防手段。

5. 作为传染性疾病的补充治疗比如肝炎。

Dendritic cell (DC) Treatment

Indications:

1-As a complement to the conventional cancer therapy.

2-As a treatment for "ulcerative colitis"

3-As a Treatment for other autoimmune diseases

4-As prevention for patients at risk for cancer and/or other diseases.

5-As a complementary treatment for infectious diseases such as Hepatitis

树突细胞免疫疗法的操作步骤:

1.抽取病人200cc血液。

2.血液需要送到瑞士的实验室,树突细胞将会从血液中提取出来,催熟,激活,提取可注射的细胞。注射前至少等待8天时间。

3.第二次注射的最佳时间点是在第一次注射之后的4-6周之后。

 

 

 

Here are the steps of DC therapy:

First, 200cc blood should be taken from patient.

Second, the blood needs to be sent to the lab in Switzerland. DCs will be isolated from the blood, matured, activated and cell free injectable extracted. Allow min. 8 days before reinjection to patient.

Third, the optimum point of time to take the second injection is around 4-6 weeks after the first vaccination.

 

 

 

 

树突细胞在肿瘤治疗方面取得的成效:

 

The Achievement of Dendritic Cells in Tumor Treatment

 

 

基于树突状细胞而设计的针对多种肿瘤的治疗技术与产品已引起世人瞩目,更为重要的是,树突状细胞免疫疗法可在患者体内诱发免疫记忆,使患者体内获得长期的抗瘤效应,防止肿瘤的复发。树突细胞免疫疗法拥有其它任何现行抗肿瘤手段所不具备的优势,为广大肿瘤患者,尤其是晚期肿瘤或因肿瘤转移而无法医治者提供一种全新、特异、高效的辅助治疗手段。

 

A variety of tumor treatment technology and products designed based on dendtitic cells attracted the attention worldwide. More importantly, dendritic cells immunotherapy can induce immune memory in the body, achieve long-term antineoplastic effect and prevent the recurrence of the tumor. Dendritic cells immunotherapy has the advantages that other treatments do not possess. It provide a new specific and efficient auxiliary treatment for the tumor patients, especially the patients in advanced cancer or with tumor metastasis.

 

应用DC细胞制作疫苗用于肿瘤的免疫治疗已经取得了令人鼓舞的结果。大量研究显示DC疫苗安全,易于操作,对于一系列类型的肿瘤均有免疫抑制作用。据国内外报道,通过树突细胞疫苗治疗的肿瘤患者许多都取得非常满意的疗效,尤其在黑色素瘤、肾细胞癌、前列腺癌等免疫性肿瘤和结直肠癌、乳腺癌、肝癌、胃癌、肺癌等,疗效更好。

 

DC cancer vaccine treatment has achieved encouraging results. A large number of studies have shown that DC cancer vaccine is safe, easy to operate and has immune inhibition to a range of cancer types. According to the reports at home and abroad, many tumor patients got satisfactory curative effect through DC treatment, especially in tumor immunity such as melanoma, renal cell carcinoma and prostate cancer, colorectal cancer, breast cancer, liver cancer, gastric cancer, lung cancer and etc.